BARBERIO, BRIGIDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.999
AS - Asia 1.710
EU - Europa 1.371
AF - Africa 498
SA - Sud America 434
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 28
Totale 7.101
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.747
SG - Singapore 512
HK - Hong Kong 311
BR - Brasile 289
IT - Italia 264
CN - Cina 247
DE - Germania 110
VN - Vietnam 105
FI - Finlandia 104
NL - Olanda 99
RU - Federazione Russa 97
PL - Polonia 90
FR - Francia 84
GB - Regno Unito 82
IN - India 42
AT - Austria 35
IE - Irlanda 33
PH - Filippine 28
AR - Argentina 27
JP - Giappone 27
MX - Messico 27
AE - Emirati Arabi Uniti 26
AU - Australia 26
EG - Egitto 26
SE - Svezia 25
ID - Indonesia 22
PK - Pakistan 22
EC - Ecuador 20
MR - Mauritania 20
AL - Albania 19
AO - Angola 19
AZ - Azerbaigian 19
CO - Colombia 19
DZ - Algeria 19
LA - Repubblica Popolare Democratica del Laos 19
HN - Honduras 18
KR - Corea 18
CL - Cile 17
DK - Danimarca 17
ES - Italia 17
GT - Guatemala 17
IL - Israele 17
RS - Serbia 17
JO - Giordania 16
KE - Kenya 16
KG - Kirghizistan 16
LV - Lettonia 16
MW - Malawi 16
NO - Norvegia 16
RE - Reunion 16
TN - Tunisia 16
TR - Turchia 16
ZA - Sudafrica 16
BE - Belgio 15
BW - Botswana 15
CA - Canada 15
JM - Giamaica 15
KH - Cambogia 15
LB - Libano 15
ME - Montenegro 15
MG - Madagascar 15
MU - Mauritius 15
PY - Paraguay 15
SK - Slovacchia (Repubblica Slovacca) 15
SN - Senegal 15
TW - Taiwan 15
ZW - Zimbabwe 15
BA - Bosnia-Erzegovina 14
CG - Congo 14
CW - ???statistics.table.value.countryCode.CW??? 14
CZ - Repubblica Ceca 14
ET - Etiopia 14
GA - Gabon 14
HR - Croazia 14
IS - Islanda 14
XK - ???statistics.table.value.countryCode.XK??? 14
AF - Afghanistan, Repubblica islamica di 13
BB - Barbados 13
CH - Svizzera 13
MZ - Mozambico 13
PA - Panama 13
PE - Perù 13
PS - Palestinian Territory 13
RO - Romania 13
TJ - Tagikistan 13
UA - Ucraina 13
UG - Uganda 13
AM - Armenia 12
BY - Bielorussia 12
BZ - Belize 12
CU - Cuba 12
DJ - Gibuti 12
GH - Ghana 12
GP - Guadalupe 12
GR - Grecia 12
IQ - Iraq 12
KZ - Kazakistan 12
SA - Arabia Saudita 12
SO - Somalia 12
YT - Mayotte 12
Totale 6.594
Salva come PNG Salva come JPEG
Città #
Fairfield 397
Singapore 344
Hong Kong 303
Ashburn 241
Chandler 210
Santa Clara 150
Seattle 134
Woodbridge 134
Cambridge 127
Houston 121
Beijing 119
San Diego 91
Wilmington 78
Boardman 73
Bytom 72
Helsinki 63
Medford 59
Padova 59
Princeton 59
Roxbury 50
Ann Arbor 46
Des Moines 40
Munich 35
Los Angeles 33
Ho Chi Minh City 32
Dong Ket 30
Chicago 28
Nuremberg 25
São Paulo 25
Dublin 24
Milan 23
Amsterdam 22
Lappeenranta 22
Baku 19
Pune 19
Vienna 19
Rotterdam 18
New York 17
Nouakchott 17
Vientiane 17
Amman 16
Hanoi 16
Luanda 16
Rome 16
London 15
Phnom Penh 15
Bishkek 14
Dakar 14
Libreville 14
Nairobi 14
Riga 14
York 14
Bridgetown 13
Harare 13
Kampala 13
Lilongwe 13
Willemstad 13
Antananarivo 12
Belgrade 12
Brazzaville 12
Brooklyn 12
Buffalo 12
Havana 12
Andorra la Vella 11
Dushanbe 11
Managua 11
Noumea 11
Reykjavik 11
Tirana 11
Ulan Bator 11
Abidjan 10
Copenhagen 10
Dili 10
Guatemala City 10
Kingston 10
Manila 10
Maputo 10
Norwich 10
Panama City 10
Yerevan 10
Accra 9
Boston 9
Cairo 9
Djibouti 9
Hefei 9
Kigali 9
Kingstown 9
Les Abymes 9
Minsk 9
Praia 9
Pristina 9
Salt Lake City 9
Sydney 9
Turku 9
Abu Dhabi 8
Addis Ababa 8
Castries 8
Dar es Salaam 8
Maitengwe 8
Mamoudzou 8
Totale 4.061
Salva come PNG Salva come JPEG
Nome #
Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis 177
Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis 169
Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria 166
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis 166
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis 159
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab 156
Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital 150
A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach 149
REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY 143
Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. 142
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 140
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 138
A survey on nutritional knowledge in coeliac disease compared to inflammatory bowel diseases patients and healthy subjects 135
Gastrointestinal: An unusual rectal finding in a patient with ulcerative colitis 132
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 132
Updates in the field of non-esophageal gastroesophageal reflux disorder 130
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility 129
Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak 120
Advancements in the use of manometry and impedance testing for esophageal functional disorders 119
Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf: Neutrophil-To-lymphocyte ratio and platelet-To-lymphocyte ratio 119
Perception of the COVID-19 pandemic among patients with inflammatory bowel disease in the time of telemedicine: cross-sectional questionnaire study 115
Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis 115
The risk of malignancies in celiac disease—A literature review 115
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation 112
Vonoprazan fumarate for the treatment of gastric ulcers: A short review on emerging data 110
Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak 109
Medical and gastroenterological education during the COVID-19 outbreak 106
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients 106
Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario 105
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 104
Vonoprazan may provide better results than ppis in helicobacter pylori eradication and beyond – is it time for a change? 103
The Lyon Consensus: Does it differ from the previous ones? 103
Prevention Strategies for Esophageal Cancer-An Expert Review 103
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study 101
Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study 101
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis 100
A Peculiar Cutaneous Manifestation in a Patient With Crohn's Disease 100
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 99
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis 98
Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis 98
Inflammatory Bowel Disease and Sleep Disturbance: As Usual, Quality Matters 93
Hospitalisation for drug infusion did not increase levels of anxiety and the risk of disease relapse in patients with inflammatory bowel disease during covid-19 outbreak 92
Modern diagnosis of early esophageal cancer: From blood biomarkers to advanced endoscopy and artificial intelligence 88
MICRO-RNAs TISSUTALI COME BIOMARCATORI DI DIAGNOSI PRECOCE E MONITORAGGIO IN PAZIENTI CON CANCRO DEL COLONRETTO ASSOCIATO A MALATTIA INFIAMMATORIA CRONICA INTESTINALE 87
Eosinophilic esophagitis: from pathophysiology to management 87
Myocarditis and inflammatory bowel diseases: A single-center experience and a systematic literature review 85
Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials: Future Treatments for EGIDS: Systematic Review 82
Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations 81
An "Old" Esophagus 79
Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases 77
Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment? 76
Reply to letter to the editor: Nlr and plr as novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf 75
Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis 74
Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis 74
Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases 73
Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey 73
Response to Khalaf et al 72
Eosinophilic esophagitis and biologics 71
Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together? 71
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem? 69
Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study 69
Bariatric Surgery and Esophageal Function: An Eternal Impasse? 68
Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms 68
Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis 65
Systematic review with meta-analysis: artificial intelligence in the diagnosis of oesophageal diseases 64
Non-hepatic solid organ transplant in patients with inflammatory bowel disease: an ECCO CONFER Multicentre Case Series 61
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series 61
Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome 61
Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis 59
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis 58
Totale 7.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.625
article - articoli 30.415
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021483 0 0 0 2 5 110 110 37 65 39 14 101
2021/2022927 38 56 66 43 115 105 86 44 106 46 42 180
2022/2023514 106 11 24 69 69 59 6 34 57 13 47 19
2023/2024495 41 53 53 41 38 45 45 36 29 14 59 41
2024/20251.949 6 172 99 52 225 52 88 142 177 113 337 486
2025/20262.619 386 615 1.030 588 0 0 0 0 0 0 0 0
Totale 7.187